International Journal of Pharmaceutical Investigation, 2023, 13, 3, 646-650.
DOI:10.5530/ijpi.13.3.080
Published: July 2023
Type: Original Article
Authors:
Glara Anest Francis
National Institute of Siddha, Tambaram Sanatorium, Chennai, Tamilnadu, INDIA.
Sureka Arumugam
National Institute of Siddha, Tambaram Sanatorium, Chennai, Tamilnadu, INDIA.
Sabari Girija Navaneetha Krishnan
National Institute of Siddha, Tambaram Sanatorium, Chennai, Tamilnadu, INDIA.
Ramamurthy Murugan
Department of Noinadal, National Institute of Siddha, Tambaram Sanatorium, Chennai, Tamilnadu, INDIA.
Christian Gnanaraj Johnson
Department of Noinadal, National Institute of Siddha, Tambaram Sanatorium, Chennai, Tamilnadu, INDIA.
Moses Erin Johnson Christian
Caucasus International University, Tbilisi, GEORGIA.
Meenakumari Ramasamy
National Institute of Siddha, Tambaram Sanatorium, Chennai, Tamilnadu, INDIA.
ABSTRACT
Introduction: Ovarian cancer is the fifth most common cause of cancer which causes more deaths than any other cancer of the female reproductive system because there is no effective screening and most women are diagnosed at advanced stages. The probability of survival at 5 years is less than 30%, and the limitation is that it will not respond to chemotherapy protocol and surgery as well. Nandhi mezhugu is a Siddha herbo-mineral drug widely used to treat cancer. Hence, the present study was intended to evaluate the anti-cancer activity of Nandhi mezhugu on (PA-1) cell line through MTT assay. Materials and Methods: Stock solutions were prepared from the formulation at various concentrations with serial dilution. Compared with the control and Methotrexate, the extracts were tested using MTT assay at different concentrations. Results: This study substantiated that the percentage of cell viability of cell line viability decrease with increase in concentration of the test drug NM. Least viability of cell was observed at the concentration of 200μg/mL was 73.02 ± 4.584%, followed by this at 100 μg and 50 μg shows 82.36 ± 3.084%, 87.81 ± 2.657, similarly 10 μg/mL shows 95.89 ± 1.054% cell viability in MTT assay. Conclusion: Thus, the current study brings forth scientific evidence for the efficacy of Nandhi mezhugu against the ovarian cancer (PA1) cell line.
Keywords: Anti-cancer activity, Ovarian cancer, Nandhi mezhugu, PA1 cell line, Siddha.